When these mice were treated with CD19.28, B7-H3.28, or CCR2b.B7-H3.28 CAR-T cells, we found that CCR2b.B7-H3.28 CAR-T cells continued showing superior antitumor activity against the tumor lesions in the brain (Fig. 6a–d). The gene discussed is CD19; the disease is neoplasm.